Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. Biotropics Malaysia...
Pantai Hospital Kuala Lumpur Advances Adult Congenital Heart Care with First Minimally Invasive PDA Device Closure
KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter device occlusion of a patent ductus arteriosus (PDA) in an adult patient with congenital heart disease — a first for the hospital's Interventional Cardiology Laboratory (ICL). The patient, who was initially referred for open-heart...
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 6, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images...
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China’s Biopharma Trailblazers and Global Collaboration
NEWARK, Del., June 6, 2025 /PRNewswire/ -- China's influential innovative drug asset cooperation platform BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration...
Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO
SHANGHAI, June 5, 2025 /PRNewswire/ -- At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUC) were presented by Prof. Xinan Sheng,...
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
HIGHLIGHTS Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs). DISCO compared the diagnostic performance of 64Cu-SARTATE at an average of 4 hours (between 3 to 5 hours) and 20 hours...
Visionary Holdings Officially Establishes Visionary Health Technology Group Limited to Accelerate Layout in HealthTech and Greater Health Industry
TORONTO, June 5, 2025 /PRNewswire/ -- On May 21, 2025, Visionary Health Technology Group Limited, a holding subsidiary of Visionary Holdings (Nasdaq: GV), was officially established in Hong Kong. This move marks a significant step in Visionary Holdings' strategic deployment in the fields of HealthTech and the greater health industry. Mr. Junfeng Li, an experienced professional in the HealthTech and...
QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel...
BioDlink Strengthens Global Compliance with Argentina GMP Certification
Global Milestone: GMP certification from Argentina, marking a key step in its global expansion and regulatory recognition. Scalable, Trustworthy Solutions: With advanced manufacturing capabilities, BioDlink deliver Pusintin® (bevacizumab) injection that are not only consistent and cost-effective, but a superior choice for markets seeking dependable therapeutic alternatives. Client-Centric Expansion: Strengthened partnership...
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic...
